Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Estelle
Product Overview
Alternative Name:
Estetrol (E4) + Progestin Combined Pill
Development Status:
Active Development
Target:
Female
Mode:
Hormonal
Delivery Type:
Oral
Duration Type:
Short-acting
Description:
20mg E4 plus a progestin in an oral contraceptive.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
estetrol (E4)
,
progestin
Potential Multi-Purpose Technology (MPT):
No
Duration:
one day
Dose:
20 mg E4, TBD progestin
Partner:
Actavis
Status
Project Phase:
Late Development
Project Stage:
Phase II
Began discovery in:
2001
Status Details:
In 2012, the clinical phase II development of Estelle was completed.
Programmatic Considerations
Considerations:
E4 is produced by human fetal liver. As a natural steroid, E4 is expected to be less thrombogenic than synthetic estrogens.
E4 may protect against osteoporosis and breast cancer.
Additional Information
Additional Information:
Pantarhei BioScience Fact Sheet:
Estretol in Oral Contraception
Footnotes:
Pantarhei Bioscience is no longer involved in development.
Download Product Report
